Ascletis Pharma (HKG:1672) said it has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Sept. 7.
The inclusion allows mainland Chinese investors to trade the biotech company's Hong Kong-listed shares through the Stock Connect platform, according to a Monday Hong Kong bourse filing.
Shares of the drugmaker rose over 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments